Compounded semaglutide is a GLP-1 receptor agonist available as a once-weekly subcutaneous injection
For type 2 diabetes, the ADA puts attributable annual spending at $12,022 per person
A feature is that one dose of medication is injected just by pressing a button, eliminating the need to set the dosage or handle injection needles
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): A randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
[1] [2] Unlike phentermine's central nervous system stimulation, tirzepatide works through multiple mechanisms: it enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central pathways